top of page

Protocol publications (select each protocol)

Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (NIH HEAL Initiative)

Emergency Department-INitiated bupreNOrphine and VAlidaTIOn Network Trial (ED-INNOVATION)

Sub Study: Emergency Department-INitiated bupreNOrphine and VAlidaTIOn Network Trial (ED-INNOVATION)

Racial/Ethnic Disparities in Addiction Treatment Access for Opioid Use Disorder from the Emergency Department

Emergency Medicine Opioid Data Infrastructure: Key Venue to Address Opioid Morbidity and Mortality (Project CODE PRO--Capturing Opioid Use Disorder Electronically and Patient Reported Outcomes)

Emergency Department Connection to Care with Buprenorphine for Opioid Use Disorder (ED-CONNECT)

Sub Study: Emergency Department Connection to Care with Buprenorphine for Opioid Use Disorder (ED-CONNECT)

Primary Care Opioid Use Disorder (PROUD) Treatment Trial

Opioid Use Disorder in the Emergency Department (Project ED Health)

Retrospective Evaluation of High Dose Buprenorphine Induction in the Emergency Department for Opioid Use Disorder

The Impact of COVID-19 on Individuals with Opioid Use Disorder Who Received Emergency Department Care: A Survey Study of Project ED Health Participants and Medical Leadership at Four EDs

Validating 3 Substance Use Screening Tools for Adolescents

Prescription Opioid Addiction Treatment Study (POATS)

MET (Motivational Enhancement Treatment) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse

MI (Motivational Interviewing) to Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse

Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse

Recent Publications

​

New Publication including a NEC Node Participating Site (Boston Medical Center): Liu J, Pan Y, Nelson MC, Gooden LK, Metsch LR, Rodriguez AE, Tross S, Del Rio C, Mandler RN, Feaster DJ. Strategies of Managing Repeated Measures: Using Synthetic Random Forest to Predict HIV Viral Suppression Status Among Hospitalized Persons with HIV. AIDS Behav. 2023 Sep;27(9):2915-2931. doi: 10.1007/s10461-023-04015-1. Epub 2023 Feb 5. PMID: 36739589; PMCID: PMC10403627.

​

Cowan E, Perrone J, Dziura J, Edelman J, Hawk K, Herring A, McCormack R, Alexandra M, Phadke M, Fiellin DA, D’Onofrio G. Urine Toxicology Profiles of Emergency Department Patients with Untreated Opioid Use Disorder: A MultiSite View. J Emerg Med. doi: 10.1016/j.jemermed.2023.06.007

 

Levy S, Minegishi M, Brogna M, Subramaniam G, McCormack J, Weiss R, Weitzman ER. Comparing the Performance of WMH-CIDI-SAM in Adolescents to Diagnoses Made by Pediatric Addiction Medicine Specialists. Journal of Addiction Medicine, in press.

​

Luo SX, Feaster DJ, Liu Y, Balise RR, Hu MC, Bouzoubaa L, Odom GJ, Brandt L, Pan Y, Hser YI, VanVeldhuisen P, Castillo F, Calderon AR, Rotrosen J, Saxon AJ, Weiss RD, Wall M, Nunes EV. Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA Psychiatry. 2023 Oct 4:e233596. doi: 10.1001/jamapsychiatry.2023.3596. Epub ahead of print. PMID: 37792357; PMCID: PMC10551817.

​

Ren Boyu, Lipsitz Stuart R, Weiss Roger D, Fitzmaurice Garrett M. Methods for handling missing binary data in substance use disorder trials. Drug Alcohol Depend. 2023 Sep 1;250:110897. doi: 10.1016/j.drugalcdep.2023.110897. Epub 2023 Jul 13. PMID: 37544038.

​

Paschen-Wolff M, Greenfield SF, Kathryn McHugh R, Burlew K, Pavlicova M, Choo TH, Barbosa-Leiker C, Ruglass LM, Mennenga S, Rotrosen J, Nunes EV, Campbell ANC. Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder. Am J Addict. 2023 Aug 15. doi: 10.1111/ajad.13463. Epub ahead of print. PMID: 37583120.

​

Cowan E, Perrone J, Bernstein SL, Coupet E Jr, Fiellin DA, Hawk K, Herring A, Huntley K, McCormack R, Venkatesh A, D'Onofrio G. National Institute on Drug Abuse Clinical Trials Network Meeting Report: Advancing Emergency Department Initiation of Buprenorphine for Opioid Use Disorder. Ann Emerg Med. 2023 Sep;82(3):326-335. doi: 10.1016/j.annemergmed.2023.03.025. Epub 2023 May 12.PMID: 37178101

 

McCormack RP, Rotrosen J, Gauthier P, D'Onofrio G, Fiellin DA, Marsch LA, Novo P, Liu D, Edelman EJ, Farkas S, Matthews AG, Mulatya C, Salazar D, Wolff J, Knight R, Goodman W, Williams J, Hawk K.Implementing Programs to Initiate Buprenorphine for Opioid Use Disorder Treatment in High-Need, Low-Resource Emergency Departments: A Nonrandomized Controlled Trial. Ann Emerg Med. 2023 Sep;82(3):272-287. doi: 10.1016/j.annemergmed.2023.02.013. Epub 2023 May 2.PMID: 37140493

​

D’Onofrio G, Hawk KF, Perrone J, et al. Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl. JAMA Netw Open. 2023;6(3):e236108. doi:10.1001/jamanetworkopen.2023.6108 

​

Kropp FB, Smid MC, Lofwall MR, Wachman EM, Martin PR, Murphy SM, Wilder CM, Winhusen TJ. Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080 MOMs study. J Subst Use Addict Treat. 2023 Apr 4;149:209030. doi: 10.1016/j.josat.2023.209030. Epub ahead of print. PMID: 37023858. https://pubmed.ncbi.nlm.nih.gov/37023858/

bottom of page